MARCHESELLI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.869
EU - Europa 6.207
AS - Asia 3.809
OC - Oceania 471
AF - Africa 157
SA - Sud America 138
Continente sconosciuto - Info sul continente non disponibili 10
Totale 24.661
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.473
GB - Regno Unito 2.479
IT - Italia 908
CN - Cina 653
DE - Germania 579
SE - Svezia 565
SG - Singapore 549
AU - Australia 439
PH - Filippine 421
HK - Hong Kong 399
TR - Turchia 389
CA - Canada 332
FR - Francia 271
UA - Ucraina 247
IR - Iran 239
FI - Finlandia 192
IN - India 147
IE - Irlanda 122
BG - Bulgaria 112
PK - Pakistan 112
VN - Vietnam 103
ID - Indonesia 99
JP - Giappone 94
MY - Malesia 92
NL - Olanda 90
KR - Corea 86
ES - Italia 80
GR - Grecia 79
BR - Brasile 78
TW - Taiwan 77
IL - Israele 68
BE - Belgio 63
RU - Federazione Russa 60
PL - Polonia 58
SA - Arabia Saudita 54
TH - Thailandia 44
GE - Georgia 38
NP - Nepal 37
NO - Norvegia 36
RO - Romania 36
ZA - Sudafrica 36
AT - Austria 34
NZ - Nuova Zelanda 32
MX - Messico 29
CH - Svizzera 27
MA - Marocco 26
KE - Kenya 25
LT - Lituania 24
EE - Estonia 22
JO - Giordania 20
PT - Portogallo 19
CZ - Repubblica Ceca 18
LK - Sri Lanka 18
BZ - Belize 14
HR - Croazia 14
NG - Nigeria 14
SI - Slovenia 14
SK - Slovacchia (Repubblica Slovacca) 14
CL - Cile 13
EG - Egitto 13
HU - Ungheria 12
AR - Argentina 10
PE - Perù 10
DK - Danimarca 9
EC - Ecuador 9
LV - Lettonia 9
TN - Tunisia 8
CY - Cipro 7
OM - Oman 7
PR - Porto Rico 7
A2 - ???statistics.table.value.countryCode.A2??? 6
BD - Bangladesh 6
CO - Colombia 6
ET - Etiopia 6
MO - Macao, regione amministrativa speciale della Cina 6
MV - Maldive 6
AE - Emirati Arabi Uniti 5
GY - Guiana 5
KZ - Kazakistan 5
MU - Mauritius 5
EU - Europa 4
IQ - Iraq 4
KW - Kuwait 4
NA - Namibia 4
QA - Qatar 4
SD - Sudan 4
BH - Bahrain 3
BO - Bolivia 3
GH - Ghana 3
GP - Guadalupe 3
LB - Libano 3
RS - Serbia 3
CR - Costa Rica 2
DO - Repubblica Dominicana 2
LU - Lussemburgo 2
MD - Moldavia 2
MT - Malta 2
MW - Malawi 2
PA - Panama 2
PS - Palestinian Territory 2
Totale 24.628
Salva come PNG Salva come JPEG
Città #
Fairfield 1.815
Southend 1.619
Santa Clara 1.261
Woodbridge 1.142
Ashburn 992
Chandler 839
Houston 809
Seattle 678
Wilmington 643
Cambridge 587
Jacksonville 503
Dearborn 428
Ann Arbor 404
Nyköping 401
Singapore 395
Hong Kong 330
Modena 223
Beijing 195
Redwood City 183
San Diego 177
Frankfurt am Main 176
New York 153
Izmir 144
Princeton 116
Helsinki 111
Sofia 110
London 104
Melbourne 97
Eugene 96
Shanghai 72
Dublin 67
Bremen 59
Ottawa 59
Milan 57
Brisbane 56
Istanbul 52
Falls Church 46
Jakarta 46
Bologna 45
Sydney 44
Taipei 44
Paris 38
Brussels 37
Fremont 37
Des Moines 36
Hanoi 35
Dong Ket 34
Athens 31
Tehran 29
Norwalk 28
Perth 27
Phoenix 26
Tokyo 26
Munich 25
Quezon City 25
Greenwich 24
Manila 24
Nanjing 24
San Giuliano Milanese 24
Toronto 24
Birmingham 23
Islamabad 23
Rome 23
Chicago 22
Kuching 22
Laval 22
San Jose 22
Tbilisi 22
Boardman 21
Ho Chi Minh City 21
Kathmandu 21
Riyadh 21
Parma 20
Davao City 19
Bengaluru 18
Cebu City 18
Karachi 18
Kuala Lumpur 18
Cagayan de Oro 17
Guangzhou 17
Kunming 17
Lahore 17
Ankara 15
Antalya 15
Auckland 15
Banqiao 15
Delhi 15
Makati City 15
Seoul 15
Tallinn 15
Tralee 15
Warsaw 15
Belize City 14
Los Angeles 14
Adelaide 13
Bangkok 13
Manchester 13
Nairobi 13
Saint Petersburg 13
San Francisco 13
Totale 16.630
Salva come PNG Salva come JPEG
Nome #
Empathy and burnout: an analytic cross-sectional study among nurses and nursing students 5.741
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 530
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma 530
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lmphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi 524
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 331
The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts 306
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 267
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 261
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 261
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 250
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 250
Incidence, clinical features and possible etiology of early onset (≤40 years) colorectal neoplasms. 249
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 249
The outcome of peripheral t-cell lymphoma patients failing first-line therapy: A report from the prospective, international t-cell project 244
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 240
Empathic attitudes among nursing students: a preliminary study 240
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 238
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network 238
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 229
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. 229
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 226
ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. 225
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 215
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 215
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. 211
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 211
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 207
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies 207
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 205
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 204
Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project 204
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 204
A multicenter retrospective clinical study of CD5/CD10-negative chronic B cell leukemias. 203
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 199
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis 198
Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study 197
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 197
Cancer incidence, mortality, and survival in Eastern Libya: Updated report from the Benghazi Cancer Registry 194
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 193
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 191
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 188
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 187
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi 187
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 185
Role of Glutathione-S-Transferase (GST) polymorphisms in patients with advanced Hodgkin Lymphoma: results from the HD2000 GISL Trial 185
Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST 184
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 183
Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study 182
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi 182
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 182
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 181
Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. 180
Estimating survival in newly diagnosed cancer patients: use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. 178
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 177
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfom 177
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma 176
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 174
Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced hodgkin lymphoma: A study by fondazione Italiana Linfomi 174
The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL) 173
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 169
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 168
A NON-LINEAR CORRELATION MODEL FOR THE RELATIVE PERMITTIVITY OF TERNARY AMPHIPROTIC (SOLVENT) MIXTURES 167
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 167
2-methoxyethanol - water solvent system : static relative permittivity from -10 to 80°C 164
Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. 164
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 163
Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: Results from a study of the Fondazione Italiana Linfomi 163
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 161
ANALYSIS OF HEAVY-METALS IN ACETO-BALSAMICO-TRADIZIONALE-DI-MODENA BY FLAME ATOMIC-ABSORPTION SPECTROSCOPY 160
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 160
Standard “off-the-shelf” multibranched thoracoabdominal endograft in urgent and elective patients with single and staged procedures in a multicenter experience 159
N,N-DIMETHYLFORMAMIDE-2-METHOXYETHANOL SOLVENT SYSTEM - DENSITIES AND EXCESS MOLAR VOLUMES AT VARIOUS TEMPERATURES 158
The relative permittivity of the ternary 1,2-ethanediol + 2-methoxyethanol + water solvent system 156
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 154
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 153
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 152
Watchful waiting in low-tumorburden follicular lymphoma in the Rituximab era. Results of a F2 observational 151
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 149
Dielectric properties of ethane-1,2-diol + 2-methoxyethanol + water liquid ternary mixtures 148
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. 147
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study) 147
Twenty-years experience with de novo metastatic breast cancer 142
CLIPI: a new prognostic index for indolent cutaneos B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 142
Phase II Fludarabine and Cyclophosphamide for the treatment of indolent cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi. 141
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 138
Durability and efficacy of tibial arterial stent placement for critical limb ischemia 134
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 133
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 130
I tumori nelle provincie di Parma, Reggio Emilia, Modena 126
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 125
The Relative Permittivity of N,N-Dimethylformamide/1,2-Dimethoxyethane Binary Mixtures from -10 to 40 C 122
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 117
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 115
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 113
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 113
Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL) 103
Influence of Thoracic Endovascular Repair on Aortic Morphology in Patients Treated for Blunt Traumatic Aortic Injuries: Long Term Outcomes in a Multicentre Study 102
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma 99
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 93
Influence of Type of Fixation and Other Characteristics on Outcome after Endovascular Repair of Ruptured Abdominal Aortic Aneurysms 91
Totale 24.707
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.918 0 0 0 0 0 633 672 445 481 248 251 188
2020/20214.312 350 180 369 436 515 373 284 439 293 452 371 250
2021/20223.136 194 240 388 194 143 218 170 207 338 260 489 295
2022/20233.279 285 357 233 328 359 401 144 304 390 151 180 147
2023/20243.220 111 149 218 250 622 263 469 377 110 180 218 253
2024/20252.572 195 113 193 476 1.102 493 0 0 0 0 0 0
Totale 25.070